Statin Combined with Amlodipine Treats Primary Aldosteronism

Last updated: November 19, 2024
Sponsor: Third Military Medical University
Overall Status: Active - Recruiting

Phase

4

Condition

Vascular Diseases

Stress

Circulation Disorders

Treatment

Simvastatin combined with Amlodipine besylate

Amlodipine besylate combined Spironolactone

Atorvastatin combined with Amlodipine besylate

Clinical Study ID

NCT06523465
STOP-PA
  • Ages 18-70
  • All Genders

Study Summary

The drug treatment for primary aldosteronism (PA) is limited and difficult to improve long-term cardiovascular outcomes. This study plans to enroll patients with primary aldosteronism and randomly divide into 3 groups: scheme 1: Statin combined with amlodipine besylate, scheme 2: Statin combined with Spironolactone and Amlodipine besylate. scheme 3: Amlodipine besylate combined with Spironolactone , to observe the changes in plasma aldosterone level, 24-hour urinary aldosterone, blood pressure, and long-term cardiovascular risk.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Clinical diagnosis of primary aldosteronism

Exclusion

Exclusion Criteria:

  • Allergy to drugs in this study

  • Pregnancy

  • Severe liver and kidney dysfunction

  • Mental illness

Study Design

Total Participants: 180
Treatment Group(s): 5
Primary Treatment: Simvastatin combined with Amlodipine besylate
Phase: 4
Study Start date:
September 10, 2024
Estimated Completion Date:
September 30, 2026

Connect with a study center

  • No. 10 Changjiang River Branch, Yuzhong District,Chongqing, China

    Chongqing, Chongqing 400042
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.